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Abstract
Background: Cardiac glycosides are Na
+/K
+-pump inhibitors widely used to treat heart failure. They are also highly
cytotoxic, and studies have suggested specific anti-tumor activity leading to current clinical trials in cancer patients.
However, a definitive demonstration of this putative anti-cancer activity and the underlying molecular mechanism has
remained elusive.
Methodology/Principal Findings: Using an unbiased transcriptomics approach, we found that cardiac glycosides inhibit
general protein synthesis. Protein synthesis inhibition and cytotoxicity were not specific for cancer cells as they were
observed in both primary and cancer cell lines. These effects were dependent on the Na
+/K
+-pump as they were rescued by
expression of a cardiac glycoside-resistant Na
+/K
+-pump. Unlike human cells, rodent cells are largely resistant to cardiac
glycosides in vitro and mice were found to tolerate extremely high levels.
Conclusions/Significance: The physiological difference between human and mouse explains the previously observed
sensitivity of human cancer cells in mouse xenograft experiments. Thus, published mouse xenograft models used to
support anti-tumor activity for these drugs require reevaluation. Our finding that cardiac glycosides inhibit protein synthesis
provides a mechanism for the cytotoxicity of CGs and raises concerns about ongoing clinical trials to test CGs as anti-cancer
agents in humans.
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Introduction
The positive inotropic effects of Digitalis purpurea extracts werefirst
recognizedovertwocenturiesagoanddigitalis-likecompounds(also
called cardiac glycosides (CGs) or cardiotonic steroids) are still
widely used in the treatment of chronic heart failure [1]. Since the
mid 1960s numerous papers have proposed putative anti-cancer
effects of CGs [1,2,3,4]. CGs show in vitro activity against a broad
range ofcell types and a numberof compound screenshaverecently
rediscovered that CGs inhibit proliferation in various assays
[2,5,6,7]. A putative anti-cancer activity for CGs is supported by
several case-control and cohort studies that loosely correlated CG
treatment withlower cancer recurrence or incidence[8,9,10,11,12].
Furthermore, using mouse models, CGs were shown to inhibit skin
carcinogenesis and reduce xenograft tumor load [6,13,14,15,16].
Particularly the strong effects in xenograft mouse models have
provided a basis for the current clinical testing of these drugs
and their derivatives (ClinicalTrials.gov id. NCT00281021,
NCT00650910 NCT00017446, www.unibioscreen.com/news).
As promising as CGs may sound as potential anti-cancer agents,
the field is not without controversy. For instance, several reports
have disputed the initial clinical studies and successful randomized
trials have thus far not been reported [17,18]. Furthermore, upon
close scrutiny the evidence for the widely cited specificity of CGs for
cancerous cells over normal cells is mostly speculative [2,3]. Finally,
themousexenograftexperimentsshouldbeinterpretedwithcaution
because rodent cells are inherently insensitive for CGs [19,20].
The mode of actionof CGs on heart output has been well defined
[1]. Low therapeutic doses of CGs result in a minimal reduction of
the Na
+/K
+ ATPase activity and raise intracellular sodium levels.
This leads to an increase of calcium ions in cardiac myocytes and
increases cardiac contractility. The therapeutic window of CGs is
small and despite careful monitoring of patient serum levels,
intoxication is a frequent treatment complication [21]. In contrast,
the mechanism underlying CG-mediated cytotoxicity has not been
conclusively addressed. Recent studies have suggested that CGs
impinge on various signal transduction pathways, including NF-
kappaB activation through CG-induced calcium oscillations
PLoS ONE | www.plosone.org 1 December 2009 | Volume 4 | Issue 12 | e8292[22,23]. However, effects of CGs on intracellular signaling have not
been linked directly to inhibition of tumor cell proliferation, leaving
the relevance of these findings unclear.
We used a large compendium of mRNA signatures derived
from cells treated with drugs to investigate the mechanism of
action of CG-mediated cytotoxicity [24]. Using this unbiased
approach we unexpectedly discovered that CGs are potent general
protein synthesis inhibitors in a variety of normal and transformed
human cells. Whereas drugs such as sirolimus (rapamycin) that
inhibit the translation of a specific subset of mRNAs are now used
to treat certain neoplasms, the general protein synthesis inhibitors
have proven to be very toxic and not useful in the treatment of
cancer [25,26,27,28,29,30]. Therefore, our findings have direct
implications for the validity of CGs as promising cancer drugs and
discourage further clinical testing of cardiac glycosides or their
derivatives as anti-cancer agents.
Results
Cardiac Glycosides Inhibit JAK2 Protein Expression
While performing a screen to identify compounds that inhibit
the activity of oncogenic JAK2 kinase, we identified several that
reduced JAK2 protein levels, including a number of CGs
(Figure 1a). Cardiac glycosides represent a group of structurally
highly related molecules that all inhibit the Na
+/K
+ ATPase.
Because CGs had been proposed to have anti-cancer activity, we
decided to study these compounds further. Dose-response
experiments showed that JAK2 protein levels were inhibited by
digitoxin, a commonly used CG, in the nanomolar range (50–
100 nM) whereas the loading controls beta-actin and PCNA were
affected much less (Figure 1b and Figure 1d). The reduction of
JAK2 correlated with the growth inhibition of cells exposed to
digitoxin (Figure 1c). JAK2 protein reduction was not due to
changes in mRNA transcription or stability (Figure 1d, Figure S1).
Cardiac Glycosides Inhibit General Protein Synthesis
To address the mechanism of action of CGs on JAK2 protein
levels in an unbiased manner we used a compendium of mRNA
signatures derived from cell lines exposed to 1309 compounds,
including CGs [24]. These gene expression signatures represent
molecular footprints of the drugs on cellular state. Drugs targeting
a common pathway cluster together even when they inhibit
different proteins and the approach has been used successfully to
study the mechanism of action of compounds [31,32]. We found
Figure 1. Cardiac glycosides reduce JAK2 protein levels and inhibit proliferation of JAK2 V617F mutant expressing HEL cells. (A)
Effects of compounds identified in a drug screen (1140 drugs from the Prestwick Library) on JAK2 protein expression. Human erythroleukemic HEL
cells were exposed to the indicated compounds at a concentration of 5 mM for 6 hours. Cells were harvested and lysates were subjected to Western
blotting using antibodies against JAK2 or actin. Compounds of the cardiac glycoside family are indicated in red. (B) HEL cells were treated with
various concentrations of digitoxin as indicated for 16 hours. Equal cell numbers were harvested and expression of JAK2 and actin was determined by
Western blotting. (C) HEL cells were cultured in the presence of the indicated concentrations of digitoxin (1 nM–1 mM) for 48 hours. Proliferation of
cells was measured using the CellTiter-Glo assay. Results represent the mean 6 S.D. of three independent experiments. (D) Human embryonic kidney
cells (HEK293T) were transfected with JAK2 V617F and treated with various concentrations of digitoxin for 16 hours as indicated. Equal numbers of
cells were harvested and protein expression levels of JAK2 and PCNA were quantified by dot blotting.
doi:10.1371/journal.pone.0008292.g001
CGs Block Protein Synthesis
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levels (Figure 1a), highly correlated with anisomycin and
cycloheximide, both well-known protein synthesis inhibitors
(Fig. 2a). Queries with three other CGs gave similar results (Table
S1).
To exclude the possibility that protein synthesis inhibitors
correlate strongly with many compounds, we next performed a
reverse query with anisomycin. The most highly correlated
compounds were other known protein synthesis inhibitors followed
closely by several CGs (Figure 2b). Notably, five CGs were more
similar to anisomycin than the well-characterized protein synthesis
inhibitor puromycin.
These results suggest that these compounds have a common
effect on cellular physiology and that the main downstream effect
of CGs is protein synthesis inhibition. This provided an
explanation for the observed effect on JAK2 protein levels, which
has a relatively short half-life [33]. The levels of a panel of other
short-lived endogenous proteins was also significantly reduced
(Figure S2). The limited effect of digitoxin on PCNA and actin
protein levels used as the loading controls can be explained by
their longer half-lives of 20 hours and 1–2 days, respectively
[34,35].
To directly measure the effect of digitoxin on protein synthesis,
we performed
35S-methionine/cysteine protein labeling experi-
ments. To exclude the possibility that a reduction of protein
synthesis would be due to cytotoxic effects of digitoxin we chose a
time point at which there were no discernable effects on cell
viability. We observed strong inhibition of protein synthesis in
human osteosarcoma cells (U2OS) at digitoxin concentrations as
low as 50 nM within 6 hours (Figure 3a). These concentrations
approximate the maximum tolerable plasma levels in humans.
Similar results were obtained in Hela cells (Figure S3). Given
protein synthesis is an essential cellular function, we would expect
CGs to be equally toxic to normal cells as to cancer cells.
Figure 2. C-map query reveals functional similarity between CGs and protein synthesis inhibitors. (A) A gene-expression signature for
digitoxigenin was used to search for compounds with a similar mechanism of action. The ten compounds showing the strongest positive
connectivity with the digitoxigenin signature from the 1,309 compounds in the C-map database, including the query compound are listed (left
panel). The number of independent experiments (i.e. treatments) with each compound (n) and their set-wise enrichment scores are shown. All
experiments in the C-map are rank-ordered according to connectivity score of the query signature in the ‘‘green-grey-red’’ barview (middle panel). All
four experiments with anisomycin (black lines) cluster at the top of the green area in the bar, indicating strong and reproducible correlation with
digitoxigenin. The best matching anisomycin gene-expression profile (instance id 1304) was directly compared with the gene-expression signature of
digitoxigenin treated cells (right panel). The gene probes (22,283) are ordered according to differential expression of the anisomycin vs. vehicle
control (left, upregulated; right, downregulated). That many of the genes regulated by anisomycin are similarly affected by digitoxigenin is illustrated
by the Kolmogorov-Smirnov (KS) plot. The score (y-axis) is high at the left side of the graph because many of the genes that are upregulated (green
line) by anisomycin are also upregulated by digitoxigenin. The converse is true for the downregulated genes (red line). 1 CG=cardiac glycoside,
PSI=protein synthesis inhibitor, AH=anti-hypertensive, 6 All enrichment scores have permutation p-values of ,0.000001. (B) A similar query as in
Figure 2a is shown but using an anisomycin signature. The best matching digitoxigenin signature (instance id 1339) was used for the Kolmogorov-
Smirnov (KS) plot (right panel).
doi:10.1371/journal.pone.0008292.g002
CGs Block Protein Synthesis
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inhibited in primary human diploid lung fibroblasts (IMR-90 cells,
Figure 2d). Effects on protein synthesis became visible after two
hours of digitoxin treatment whereas maximum effects were
achieved after 4 hours (Figure 3b). The concentration at which
protein synthesis was inhibited correlated well with cytotoxicity
and although digitoxin-mediated cytotoxicity varied between cell
types, we did not observe specificity for cancerous cells (Figure 3c
and Figure S3).
Thus, CGs efficiently block protein synthesis of both neoplastic
and non-neoplastic cells. The concentrations that inhibit protein
synthesis in vitro also block proliferation. Given protein synthesis is
required for cell growth, this suggests that the cytotoxic effect of
CGs is mediated at least in part by inhibition of protein synthesis.
Inhibition of the Na
+/K
+-ATPase Blocks Protein Synthesis
As inhibition of the Na
+/K
+-ATPase (the only known CG
target) reduces the concentration of intracellular potassium and
potassium is required for translation [36] we speculated that
inhibition of the Na
+/K
+-pump was responsible for the observed
effects on protein synthesis. To investigate this we expressed the
naturally CG-resistant alpha1-chain of the murine Na
+/K
+-pump,
which is reportedly ,1000 times less sensitive for CGs than the
human alpha1-subunit, in human cells [20]. Expression of the
murine but not the human alpha-chain largely rescued the
inhibitory effects of digitoxin on intracellular potassium levels,
protein expression and survival of HEL cells (Figure 4a-d and
Figure S4), A complete rescue of proliferation was observed in
U2OS cells (Figure S5). The incomplete rescue in HEL cells may
be due to a low expression level of the alpha-chain in a
subpopulation of the transduced cells. The previously reported
insensitivity of murine cells to CGs was also confirmed using the
murine hematopoietic BaF3 cell line, which was resistant to high
levels of digitoxin (Fig. 4e).
To further establish that the effects of digitoxin are dependent
on the Na
+/K
+-ATPase we inhibited Na
+/K
+-pump activity by
incubating cells in a sodium-free buffer. This buffer inhibited
murine and human Na
+/K
+-pump activity as determined by
intracellular potassium levels and did not affect cell viability in the
timeframe of the experiment (Figure 4f and Figure S6). Incubation
in the sodium-free buffer for 4–8 hours decreased expression of
relatively short-lived proteins such as p53 and JAK2 to a similar
Figure 3. Digitoxin inhibits protein synthesis. (A) Effects of digitoxin on
35S-Met/Cys protein incorporation in human U2-OS cells. Cells were
treated with various concentrations of digitoxin for 6 hours and equal numbers of cells were subjected to
35S-Met/Cys incorporation assay as
described in Materials and Methods. Actin was used as an additional loading control. (B) Dose- and time-dependent inhibition of
35S-Met/Cys uptake
by digitoxin in IMR90 cells. (C) Digitoxin concentrations resulting in 50% reduction in cell number (IC50) with 95% confidence intervals (CI) obtained
with neoplastic cell lines as well as with primary fibroblasts (IMR90 cells), primary human mononuclear cells (MNC, donor #1-#3) and non-
tumorigenic MCF10A cells. IC50 values were calculated in GraphPad Prism 5.0 using the nonlinear regression model for dose-response (least square
fitting, variable slope) and represent the results of three independent experiments in each case.
doi:10.1371/journal.pone.0008292.g003
CGs Block Protein Synthesis
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+/K
+ ATPase. (A) Effect of digitoxin on intracellular
potassium levels in HEL cells with overexpression of the human or murine alpha1-chain. HEL cells transduced with ATP1A1 or Atp1a1 were incubated
with digitoxin (250 nM) for 8 hours. Cells were lysed and potassium concentrations were determined (*** indicates p,0.001, * indicates p,0.05). (B)
HEL cells expressing the human or murine alpha1-subunit were treated with various concentrations of digitoxin as indicated for 6 hours and the
expression of JAK2 and actin was determined by Western blotting. Expression of the murine alpha-chain of the Na
+K
+-pump conferred resistance
against the inhibitory effect of digitoxin. (C) Effects of digitoxin (1 nM–1 mM, 48 hours) on growth of ATP1A1- or Atp1a1-overexpressing HEL cells. (D)
Microscope photograph of a cell culture dish containing ATP1A1- or Atp1a1-overexpressing cells after 5 days of exposure to 1 mM digitoxin. (E)
Growth of murine hematopoietic Ba/F3 cells is not affected by digitoxin as assessed by CellTiter-Glo assay (three independent experiments, mean 6
S.D.). (F) Effects of a sodium-free buffer on intracellular potassium levels in HEL cells overexpressing human ATP1A1 or murine Atp1a1. Cells were
cultured in a sodium-free buffer or in a control buffer for up to 8 hours as indicated and potassium concentrations were measured in cell lysates.
Exposure to the sodium-free buffer resulted in inhibition of the Na
+/K
+-pump and depletion of intracellular potassium in both cell lines (*** indicates
p,0.001). (G) Inhibition of expression of JAK2 and TP53 in HEL cells exposed to sodium-free buffer. HEL cells overexpressing human ATP1A1 or
murine Atp1a1 were cultured in sodium-free or control buffer for 8 hours and expression of JAK2 and TP53 was determined by Western blotting.
Equal numbers of cells were loaded and actin served as an additional loading control.
doi:10.1371/journal.pone.0008292.g004
CGs Block Protein Synthesis
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showed a modest decrease in the expression of these proteins,
possibly due to the lack of amino acids in the buffer. These results
further indicate that inhibition of the Na
+/K
+-pump is responsible
for the effects of CGs on protein synthesis.
Mice Tolerate High Levels of Digitoxin
Our results thus far indicate that CGs are general protein
synthesis inhibitors which are equally cytotoxic for normal and
cancer cells. How can this be reconciled with the published mouse
xenograft experiments that show efficient cytotoxicity of grafted
cells without adverse effects on the host? In agreement with
previous reports, our experiments also showed that mouse cells are
intrinsically resistant to CGs due to a reduced sensitivity of the
alpha-chain of the Na
+/K
+-pump. Based on this in vitro finding, it
would be predicted that mice tolerate much higher plasma levels of
CGs than humans. As a consequence, human xenografted cells,
whether normal or cancerous, could be exposed to drug levels far
higher than could be used in humans without affecting the murine
host. Consequently, such an experiment would be uninformative
for the human situation and provide no evidence for a therapeutic
window for CG in cancer therapy.
We therefore wished to determine the serum levels of digitoxin
upon administration of a typical dose used in published reports
and approximately 20 times lower than the maximum tolerated
dose [5,6,14,15]. The measured digitoxin serum concentration
exceeded the levels normally observed in human patients more
than 100 fold, without any observable adverse effects (Figure 5a).
Even 24 hours after injection plasma levels remained more than 10
fold higher than achievable in human patients. We conclude that
mice tolerate high levels of CGs rendering them inherently
unsuitable for in vivo xenograft experiments evaluating the
specificity of cancer cell killing.
Discussion
Our findings challenge the view that CGs or other Na
+/K
+-
ATPase inhibitors hold promise as anti-cancer drugs and therefore
have immediate consequences for the clinical evaluation of CGs as
anti-neoplastic agents. There are at least four ongoing clinical
trials in the United States and Europe testing the effect of CGs and
a CG-derivative in cancer (ClinicalTrials.gov id. NCT00281021,
NCT00650910 NCT00017446, www.unibioscreen.com/news).
Our results show no direct specificity of CGs for cancer cells,
and provide the reason by showing that they inhibit protein
synthesis. As general protein synthesis inhibitors have not proven
useful as cancer therapeutics, it is highly unlikely that the effects of
CGs on protein synthesis can be successfully exploited to treat
cancer [25,26,27,28,29,30]. Furthermore, the narrow therapeutic
window of CGs indicates that the serum levels required to achieve
protein synthesis inhibition could cause intoxication. Indeed, some
of the symptoms of CG intoxication may be due to inhibition of
protein synthesis. As therapeutic CG plasma levels used to treat
heart disease are low (,30 nM) and only result in minimal
inhibition of the Na
+/K
+ ATPase, this is unlikely to affect protein
synthesis.
Although we cannot exclude that certain tumor types may be
exquisitely sensitive for CGs, we are not aware of a study providing
evidence or mechanistic insights to support this claim. Our finding
that normal diploid fibroblasts, non-tumorigenic breast epithelial
cells (MCF10A), as well as peripheral blood mononuclear cells
Figure 5. Differential sensitivity of human and murine cells against CGs. (A) Time course of digitoxin serum levels in mice injected with
digitoxin (1 mg/kg) intraperitoneally. Each time point represents measurements from 5 animals (mean 6 S.D.). (B) Model for the principal mechanism
of action underlying the growth-inhibitory effects of cardiac glycosides. Inhibition of the Na
+/K
+ pump by cardiac glycosides leads to a depletion of
intracellular potassium which is required for the elongation step in protein synthesis [36].
doi:10.1371/journal.pone.0008292.g005
CGs Block Protein Synthesis
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mechanism of cytotoxicity most likely being general protein
synthesis inhibition, do not support a specific anti-cancer activity
for CGs.
We wish to point out that our data do not contradict a role of
the Na+/K+ pump in modulating signaling events. Indeed, it
seems that the Na
+/K
+-pump has acquired functions beyond the
maintenance of ion balance and impinges on several signaling
cascades but thus far this has not been directly linked to the
cytotoxic effects of CGs [22,23].
Several compound screens similar to our study have reported
that CGs are ‘‘specific’’ inhibitors of kallikrein [40], N-Glycan [5]
HIF1-alpha [6] and most recently p53 [41]. The choice of long-
lived control proteins used in these studies (i.e. beta-actin) masks
the effect of a block in protein synthesis in short-term assays.
Remarkably, experiments in the last two papers indicate inhibition
of general protein synthesis by CGs but these observations were
largely ignored.
It had already been shown that human cells are much more
susceptible to CGs than murine cells, as we also report here. This
differential sensitivity was used in the mid-1970s as a selection
strategy in tissue culture [19]. In light of these results, studies that
have shown anti-cancer effects of CGs in xenograft mouse
experiments need to be reevaluated.
It is well established that potassium is required for protein
synthesis [36,37,38,39]. Potassium is required for maintenance of
ribosome structure, tRNA binding to ribosomes and protein
synthesis elongation is completely blocked below 50 mM [36]. In
our experiments, we noticed ,75% reduction in K
+ levels upon
digitoxin treatment. Given that the normal intracellular potassium
concentration in cells ranges from 100 to 150 mM, this indicates
that levels drop below 50 mM when cells are exposed to digitoxin.
We therefore postulate that the inhibition of protein synthesis is
the direct consequence of intracellular potassium depletion
(Figure 5b).
In summary, our results support the idea that inhibition of the
Na
+/K
+-pump by CGs suppresses general protein synthesis in
neoplastic as well as in normal human cells. Our study provides
important insights for the basic as well as the clinical field of CG
research and reinforces the notion that detailed mechanistic
insights and solid evidence should be the basis for clinical
intervention studies.
Materials and Methods
Ethics Statement
Peripheral blood mononuclear cells (MNC) were obtained from
healthy donors after obtaining written informed consent (Institu-
tional review board of the Medical University of Vienna, Ek Nr
635/2007). All animal studies were approved by the local
institutional review committee for animal research (Institutional
Animal Care and Use Committee, IACUC) and in accordance to
national and international guidelines (approval number BMWF-
66.009/0161-II/10b/2008).
Chemicals, Cell Lines and Culture Conditions
The Prestwick Library was acquired from Prestwick Chemical,
Inc. (Illkirch, France). All other chemicals were acquired from
Sigma (St Louis, MO). HEL cells (DSMZ, Braunschweig,
Germany) were cultured in RPMI 1640 medium containing
10% fetal calf serum (FCS). BaF/3 cells (DSMZ) were maintained
in RPMI 1640 medium containing FCS and recombinant murine
IL-3 (1 ng/ml, Preprotech, Rocky Hill, NJ). IMR-90 cells (ATCC,
Rockville, MD), U2-OS cells (ATCC), A2780 cell (a gift from Dr
Alan D’Andrea), A549 cells (ATCC), MCF7 (ATCC), SK-HEP1
(DSMZ) and Hela cells (DSMZ) were cultured in DMEM
supplemented with 10% FCS. MCF10A cells (ATCC) were
culture in DMEM/F12 medium with 5% horse serum (Invitrogen)
and supplemented with EGF (20 ng/ml), hydrocortisone (0.5 ug/
ml), cholera toxin (0.1 ug/ml) and insulin (10 ug/ml). Isolated
MNCs (Ficoll) were cultured in RPMI 1640 medium containing
10% FCS in the presence of phytohemagglutinin (5 mg/mL) and
IL-2 (Peprotech; 100 U/mL). To inhibit the Na
+/K
+-pump in a
cardiac glycoside (CG)-independent way, cells were cultured in a
sodium free buffer composed of HEPES (10 mM, pH 7.4), glucose
(4.5 g/L), CaCl2 (0.2 g/L), KCl (0.4 g/L), and choline chloride
(15.4 g/L) or in the same buffer containing NaCl (6.4 g/L) instead
of choline chloride (control buffer) for up to 8 hours, as described
in Dresser et al. [42]. Transfections were carried out using
Lipofectamine2000 (Invitrogen, Carlsbad, CA), according to
manufacturers instructions.
Immunoblotting
Western blotting was carried out using antibodies against JAK2
(polyclonal rabbit antibody; Cell Signaling Technology, Beverly,
MA), b-actin (Sigma), PCNA (clone PC10; Upstate Biotechnology,
Lake Placid, NY), and p53 (clone DO1; Santa Cruz Biotechnol-
ogy, Santa Cruz, CA). In selected experiments, lysates were
directly spotted onto nitrocellulose membranes (Amersham
Biosciences, Uppsala, Sweden)
35S-Methionine/cysteine uptake.
To assess the effects of CGs on protein synthesis, cells were
cultured for 6–14 hours in the absence or presence of various doses
of digitoxin. Next, cells were labeled with
35S-Methionine/
Cysteine (Easymix, Perkin Elmer, Cambridge, UK) for 20 minutes
in methionine/cysteine-free medium (Invitrogen). After washing,
cells were lysed and subjected to SDS-PAGE. Incorporated
35S-
methionine/cysteine was detected by autoradiography.
Proliferation Assays
The effect of digitoxin on proliferation was determined using
the CellTiter-GloH assay (Promega, Madison, WI) according to the
manufacturers instructions.
Expression of the Alpha-Chain of the Na
+/K
+-Pump
The murine and human alpha-chains of the Na
+/K
+-pump
(Atp1a1, clone IRAVp968A0688D; ATP1A1, clone IR-
ATp970E0475D) were obtained from ImaGenes (Berlin, Ger-
many) and cloned into pMSCV-IRES-GFP. To stably express
these constructs, HEL cells were transduced with recombinant
VSV-G pseudotyped retroviruses. GFP-positive cells were en-
riched by cell sorting on a FACSAria machine (Becton Dickinson,
San Jose, CA).
Mice
C57/BL6 mice were purchased from the Jackson Laboratory
(Bar Harbor, ME) and injected intraperitoneally with digitoxin (1
mg/kg). Serum levels of digitoxin were determined using the
CEDIA Digitoxin-Assay (Microgenics Corporation, Fremont, CA)
on a 912 Automatic Analyzer (Hitachi, Tokyo, Japan).
Connectivity Map (C-Map) Query
A gene-expression signature for digitoxigenin was generated
using the ‘instance query’ feature from build 02 of the
Connectivity Map (www.broad.mit.edu/cmap) [24]. The signa-
ture was determined using threshold values of 0.67 and 20.67 (2-
fold changes) and included 78 up- and 122 down-regulated
Affymetrix probe sets from three independent digitoxigenin
CGs Block Protein Synthesis
PLoS ONE | www.plosone.org 7 December 2009 | Volume 4 | Issue 12 | e8292experiments (instance ids: 1339, 4217, 4801). An anisomycin
signature was generated in a similar fashion (instance ids: 1304,
2658, 6764, threshold 1.0 and 20.67). These signatures were used
to query the C-map database for compounds with similar effects
on gene expression.
Potassium Measurements
HEL cells (1610E7) were pelleted after incubation, washed
twice with 0.9% NaCl (w/v) and then lysed in water by repeated
freeze-thawing and sonication. Potassium levels were measured on
an Olympus AU2700 (Olympus, Tokyo, Japan).
Supporting Information
Figure S1 Digitoxin does not affect JAK2 mRNA levels. HEL
cells were treated with various concentrations of digitoxin as
indicated for 16 hours. Expression of JAK2 mRNA levels was
determined by quantitative real time PCR and normalized to ABL
mRNA levels.
Found at: doi:10.1371/journal.pone.0008292.s001 (9.05 MB TIF)
Figure S2 Digitoxin inhibits protein expression of a panel of
endogenous proteins. HEL cells were treated with 200 nM
digitoxin for 16 hours. Equal cell numbers were harvested and
expression of the indicated proteins was determined by Western
blotting. All antibodies were acquired from Becton Dickinson
except for Caspase-3 (Cell Signaling Technology) and TP53 (DO-
1, Santa Cruz Biotechnology).
Found at: doi:10.1371/journal.pone.0008292.s002 (9.05 MB TIF)
Figure S3 Digitoxin inhibits protein synthesis in Hela cells. Hela
cells were treated with increasing concentrations of digitoxin for 16
hours and subjected to a 35S-Met/Cys incorporation assay as
described in Materials and Methods. Equal numbers of cells were
loaded. Actin was used as an additional loading control.
Found at: doi:10.1371/journal.pone.0008292.s003 (9.05 MB TIF)
Figure S4 Overexpression of the human ATP1A1 or the murine
Atp1a1 protein in HEL cells. HEL cells were transduced
retrovirally with ATP1A1 or Atp1a1 as described in Materials
and Methods. GFP-positive cells were enriched by FACS-sorting
and expression of endogenous ATP1A1 as well as overexpressed
ATP1A1/Atp1a1 was determined by quantitative real time PCR.
The mRNA levels of overexpressed ATP1A1/Atp1a1 were found
to be approximately three-fold higher than endogenous ATP1A1
levels (DDCT=1.7 for ATP1A1 and 1.4 for Atp1a1). Results
represent the mean 6 S.D. of duplicates.
Found at: doi:10.1371/journal.pone.0008292.s004 (9.05 MB TIF)
Figure S5 Expression of the murine Atp1a1 protein renders
U2OS cells insensitive for JAK2 protein inhibition. U2OS cells
were co-transfected with JAK2 V617F and the human (ATP1A1)
or murine (Atp1a1) alpha1-subunit of the Na
+/K
+ pump. Cells
were exposed to increasing concentrations of digitoxin for 24
hours and JAK2 levels were quantified by dot blot. Shown are the
mean values of triplicates of a single experiment, including the
standard deviations.
Found at: doi:10.1371/journal.pone.0008292.s005 (9.05 MB TIF)
Figure S6 Incubation of HEL cells for 8 hours in sodium-free
buffer does not affect cell viability. HEL cells were incubated in
sodium free or control buffer for 8 hours and cell viability was
determined using the trypan blue exclusion test. Shown are the
mean values of three experiments, including standard deviations.
Found at: doi:10.1371/journal.pone.0008292.s006 (9.05 MB TIF)
Table S1 C-map queries with three cardiac glycosides reveal
functional similarity between CGs and protein synthesis inhibitors.
Similarly as described in the figure legend of Figure 2, gene
expression signatures were determined for ouabain, digoxin and
proscillaridin and used to query the connectivity map. The results
for each query are listed including the rank, compound name, the
number of independent experiments (i.e., treatments) with each
compound (n) and their set-wise enrichment scores. All enrich-
ment scores have permutation p-values of ,0.000001. CG=
cardiac glycoside, PSI=protein synthesis inhibitor, AH=anti-
hypertensive.
Found at: doi:10.1371/journal.pone.0008292.s007 (0.30 MB
DOC)
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